Based on the Adaptimmune Therapeutics Plc stock forecast from 4 analysts, the average analyst target price for Adaptimmune Therapeutics Plc is USD 1.83 over the next 12 months. Adaptimmune Therapeutics Plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adaptimmune Therapeutics Plc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Adaptimmune Therapeutics Plc’s stock price was USD 0.30. Adaptimmune Therapeutics Plc’s stock price has changed by -2.48% over the past week, +32.79% over the past month and -73.64% over the last year.
No recent analyst target price found for Adaptimmune Therapeutics Plc
No recent average analyst rating found for Adaptimmune Therapeutics Plc
Company Overview Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Read Less
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cel...Read More
Frequently Asked Questions About Adaptimmune Therapeutics Plc (ADAP) Stock
Based on ratings from 4 analysts Adaptimmune Therapeutics Plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ADAP's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ADAP is USD 1.83 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 1.4.
Unfortunately we do not have enough data on ADAP's stock to indicate if its overvalued.
The last closing price of ADAP's stock was USD 0.30.
The most recent market capitalization for ADAP is USD 0.08B.
Based on targets from 4 analysts, the average taret price for ADAP is projected at USD 1.83 over the next 12 months.
This means that ADAP's stock price may go up by +519.92% over the next 12 months.
We can't find any ETFs which contains Adaptimmune Therapeutics Plc's stock.
As per our most recent records Adaptimmune Therapeutics Plc has 506 Employees.
Adaptimmune Therapeutics Plc's registered address is 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX.
You can get more information about it from Adaptimmune Therapeutics Plc's website at https://www.adaptimmune.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Adaptimmune Therapeutics Plc (ADAP) Stock
Based on ratings from 4 analysts Adaptimmune Therapeutics Plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ADAP's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ADAP is USD 1.83 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 1.4.
Unfortunately we do not have enough data on ADAP's stock to indicate if its overvalued.
The last closing price of ADAP's stock was USD 0.30.
The most recent market capitalization for ADAP is USD 0.08B.
Based on targets from 4 analysts, the average taret price for ADAP is projected at USD 1.83 over the next 12 months.
This means that ADAP's stock price may go up by +519.92% over the next 12 months.
We can't find any ETFs which contains Adaptimmune Therapeutics Plc's stock.
As per our most recent records Adaptimmune Therapeutics Plc has 506 Employees.
Adaptimmune Therapeutics Plc's registered address is 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX.
You can get more information about it from Adaptimmune Therapeutics Plc's website at https://www.adaptimmune.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ADAP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
